GlyPerA™ effectively shields airway epithelia from SARS-CoV-2 infection and inflammatory events.
Antiviral
Prophylaxis
SARS-CoV-2
Transmission
Variants of concern
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
22 Mar 2023
22 Mar 2023
Historique:
received:
23
12
2022
accepted:
13
03
2023
entrez:
23
3
2023
pubmed:
24
3
2023
medline:
25
3
2023
Statut:
epublish
Résumé
New SARS-CoV-2 variants of concern (VOCs) and waning immunity illustrate that quick and easy-to-use agents are needed to prevent infection. To protect from viral transmission and subsequent inflammatory reactions, we applied GlyperA™, a novel antimicrobial formulation that can be used as mouth gargling solution or as nasal spray, to highly differentiated human airway epithelia prior infection with Omicron VOCs BA.1 and BA.2. This formulation fully protected polarized human epithelium cultured in air-liquid interphase (ALI) from SARS-CoV-2-mediated tissue destruction and infection upon single application up to two days post infection. Moreover, inflammatory reactions induced by the Omicron VOCs were significantly lowered in tissue equivalents either pre-treated with the GlyperA™ solution, or even when added simultaneously. Thus, the GlyperA™ formulation significantly shielded epithelial integrity, successfully blocked infection with Omicron and release of viral particles, and decreased intracellular complement C3 activation within human airway epithelial cell cultures. Crucially, our in vitro data imply that GlyperA™ may be a simple tool to prevent from SARS-CoV-2 infection independent on the circulating variant via both, mouth and nose.
Identifiants
pubmed: 36949547
doi: 10.1186/s12931-023-02397-3
pii: 10.1186/s12931-023-02397-3
pmc: PMC10032620
doi:
Types de publication
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
88Subventions
Organisme : Austrian Science Fund FWF
ID : P 33510
Pays : Austria
Informations de copyright
© 2023. The Author(s).
Références
Curr Pharm Des. 2018;24(15):1689-1694
pubmed: 29623827
Antioxidants (Basel). 2020 Sep 10;9(9):
pubmed: 32927924
JAMA Intern Med. 2022 Feb 1;182(2):153-162
pubmed: 34962505
Sci Rep. 2017 Sep 14;7(1):11644
pubmed: 28912507
Nature. 2022 Feb;602(7898):657-663
pubmed: 35016194
JAMA. 2021 Mar 2;325(9):821-822
pubmed: 33507218
J Signal Transduct. 2012;2012:329635
pubmed: 22175013
J Allergy Clin Immunol. 2021 Jun;147(6):2083-2097.e6
pubmed: 33852936
Cells. 2019 Oct 21;8(10):
pubmed: 31640299
Autoimmunity. 2021 Jun;54(4):213-224
pubmed: 33899609
J Clin Microbiol. 2022 Sep 21;60(9):e0106522
pubmed: 36036600
Biol Open. 2014 Jul 25;3(8):777-84
pubmed: 25063200
Annu Rev Biochem. 2017 Jun 20;86:715-748
pubmed: 28441057
FASEB J. 2014 Oct;28(10):4223-34
pubmed: 24958208
Int J Biochem Cell Biol. 2007;39(1):44-84
pubmed: 16978905
Proc Natl Acad Sci U S A. 2020 Mar 31;117(13):7001-7003
pubmed: 32165541
mBio. 2018 Oct 9;9(5):
pubmed: 30301856
Nat Rev Immunol. 2022 Feb;22(2):69-71
pubmed: 35046570
Sci Immunol. 2021 Apr 7;6(58):
pubmed: 33827897
mBio. 2021 Apr 27;12(2):
pubmed: 33906927
Commun Biol. 2021 Feb 1;4(1):151
pubmed: 33526793
Respir Res. 2022 Oct 31;23(1):300
pubmed: 36316674
Nat Rev Immunol. 2022 Feb;22(2):77-84
pubmed: 34912108